



July 10, 2024

To,
The Manager – Listing
BSE Limited 1st Floor,
New Trading Ring Rotunda Building,
P J Towers,
Dalal Street,
Fort, Mumbai – 400001

Ref: Scrip Code - BSE: 524632

Dear Sir

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 read with Schedule III of the Listing Regulations, we would like to inform you that meeting of the Board of Directors of Shukra Pharmaceuticals Limited (“Company”), was held today i.e. Wednesday, July 10, 2024 and inter-alia approved the following:

- 1 Took note of resignation of Mr. Mehul Patel from the post of Chief Financial Officer of the Company with effect from July 10, 2024. Kindly find enclosed herewith duly signed resignation letter of Mr. Mehul Patel. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, are provided as per **Annexure – A**.
2. Based on the recommendations of the Audit Committee and Nomination and Remuneration Committee and subject to the approval of the Shareholders of the Company, appointment of Ms. Anar Jayesh Patel (DIN: 02588388), as Additional Director (Whole-time Director), liable to retire by rotation, designated as Executive Director for a period of 3 years with effect from July 10, 2024 to July 09, 2027 and payment of remuneration of her. Ms. Anar Patel shall hold the office upto the ensuing General Meeting.

She was also appointed as a Chief Financial Officer of the Company with effect from July 10, 2024 the details as required under SEBI (Listing Obligations and Disclosure

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, are provided as per **Annexure – B.**

3. Based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of the Shareholders of the Company, appointment of Mr. Jitendra Somchand Shah (DIN: 01609325), as an Additional Director categorized as Non – Executive Independent Director of the Company, for a term of 5 consecutive years w.e.f. July 10, 2024 to July 9 2029 who shall hold the office upto the ensuing General Meeting of the Company. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, are provided as per **Annexure – C.**

The meeting of the Board commenced at 7:00 p.m. and concluded at 7:30 p.m.

You are requested to take the same on your record.

Thanking You,
Yours Faithfully,

For Shukra Pharmaceuticals Limited

Dakshesh Shah
Managing Director
DIN: 00561666



CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Annexure -A

Sr. No.	Particulars	Information
1	Name of Chief Financial officer	Mr. Mehul Patel
2	Reason for change viz. appointment, resignation removal, death or otherwise	Mr. Mehul Patel, Chief Financial Officer of the Company has resigned due to personal reasons vide his letter dated July 10, 2024.
3	Date of resignation	July 10, 2024
4	Brief Profile (in case of appointment)	N.A.

Annexure-B

Sr. No.	Particulars	Information
1	Name of Chief Financial officer	Ms. Anar Jayesh Patel
2	Reason for change viz. appointment, resignation removal, death or otherwise	Based on the recommendations of Audit Committee and the Nomination and Remuneration Committee and subject to the approval of the Shareholders, the Board of Directors of the Company has approved the appointment of Ms. Anar Jayesh Patel (DIN: 02588388), as an Additional Director (Whole-time Director), liable to retire by rotation, designated as Executive Director of the Company for a period of 3 years with effect from July 10, 2024 to July 09, 2027. and the payment of remuneration of her. Ms. Anar Patel shall hold the office upto the ensuing General Meeting. She was also appointed as Chief Financial Officer of the Company with effect from July 10, 2024
3	Date of Appointment	July 10, 2024
4	Brief Profile (in case of appointment)	Built around the core idea of "Be the change you wish to see in the world!", Anar Patel's life journey is the reflection of her aspiration and desire to catalyze social change through sustainable means. Love, trust and faith, are three core values that have woven her life journey in service,

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

		thread by thread. Anar Patel, an ardent social change maker, an MBA from Institute of Management, NIRMA University, is engaged in service for over 30 years now. She has been the pillar and driving force of many organizations serving and empowering different sections of society.
5	Disclosure of relationships between directors (in case of appointment of a director)	Mother of Executive Director Sanskriti Patel and Ms. Anar Jayesh Patel is promoter of the Company.

Annexure -C

Sr. No.	Particulars	Information
1	Name of Independent Director	Mr. Jitendra Shah
2	Reason for change viz. appointment, resignation removal, death or otherwise	Based on the recommendations of the Nomination and Remuneration Committee and subject to the approval of the Shareholders, the Board of Directors of the Company has approved the appointment of Mr. Jitendra Somchand Shah, DIN (01609325), MBA (Marketing), as an Additional Director categorized as Non – Executive Independent Director of the Company, for a term of 5 consecutive years w.e.f. 10.07.2024 to 09.7.2029 who shall hold the office upto ensuing General Meeting.
3	Date of Appointment	July 10, 2024
4	Brief Profile (in case of appointment)	Mr. Jitendra Shah is having experience of more than 42 years in Marketing, Corporate Sales, Channel Sales, Business Development and Create marketing plans and campaigns for company products.
5	Disclosure of relationships between directors (in case of appointment of a director)	Nil

Note: With reference to the directions dt: 14.6.2018 of SEBI to the Stock Exchanges and based on the declarations received, we hereby inform that the above Director is not debarred from holding the office of Director by virtue of any SEBI Order or any other such Authority.

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Thanking You,
Yours Faithfully,

For Shukra Pharmaceuticals Limited

Dakshesh Shah
Managing Director
DIN: 00561666



CIN : L24231GJ1993PLC019079

Date: 10/07/2024

To,
The Board of Directors,
Shukra Pharmaceuticals Limited
3rd floor, Dev House, Opp. WIAA,
Judges Bungalows Road, Bodakdev,
Ahmedabad, Gujarat, 380054

Sub: Resignation from the position of CFO

Dear Sir/Madam,

It has been my privilege to serve on the Board of Shukra Pharmaceuticals Limited as a Chief Financial Officer (CFO).

Due to personal reasons, I, MEHULKUMAR HARSHADBHAI PATEL, hereby resign from the position of CFO of the Company. Kindly accept this letter as my resignation with immediate effect i.e. from 10th July, 2024.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies, Gujarat and make necessary submissions to the Stock Exchange (i.e.) the BSE Limited.

I hereby confirm that there are no other material reasons other than those stated above for my resignation.

I wish the company continued prosperity and all my colleagues the very best in their future endeavours.

Thanking You,
Yours sincerely,



MEHULKUMAR HARSHADBHAI PATEL